Attorneys

r. Wierzbowski's practice focuses on securities class and derivative actions brought on behalf of defrauded investors, and the prosecution of patent infringement suits on behalf of patent-holders.

As a member of the Firm’s patent litigation group, Mr. Wierzbowski is currently prosecuting cases on behalf of Anvik Corporation against Nikon, Sharp, Samsung, and many other large electronics companies relating to Anvik’s patented technology for manufacturing the displays used in flat panel televisions, computer monitors, and other devices.

Mr. Wierzbowski is also a member of the team prosecuting a securities fraud suit against Merck and others, which arises out of Defendants’ misstated belief in the safety of Merck’s pain-killer VIOXX. The plaintiffs in that action successfully appealed the dismissal of the case to the Third Circuit Court of Appeals and the U.S. Supreme Court, which resulted in a unanimous and ground-breaking victory for investors. Mr. Wierzbowski also currently represents institutional investors in securities class actions alleging that Merck and Schering-Plough misrepresented and withheld the financially-devastating results of the ENHANCE drug trial, which called into serious question the benefits of the cholesterol-lowering drugs ZETIA and VYTORIN.

At BLB&G, Mr. Wierzbowski has also been a member of the teams that successfully litigated derivative actions on behalf of public pension funds against the individuals involved in stock option backdating, including the UnitedHealth, Monster Worldwide and Progress Software cases. For instance, in UnitedHealth, Plaintiffs achieved wide-ranging corporate governance reforms and successfully recovered hundreds of millions of dollars from the individual Defendants in the largest derivative recovery in history